Epoetin theta, sold under the brand name Biopoin among others, is a form of the human hormone erythropoietin produced using recombinant DNA technology.
It acts as a short acting erythropoiesis-stimulating agent (ESA) for the treatment of anemia associated with chronic kidney disease and chemotherapy-induced anemia in patients with cancer.
Epoetin theta is indicated for the treatment of symptomatic anemia in adults.
The most common side effects include shunt thrombosis (clots that can form in blood vessels of patients on dialysis, a blood clearance technique), headache, hypertension (high blood pressure), hypertensive crisis (sudden, dangerously high blood pressure), skin reactions, arthralgia (joint pain) and influenza (flu)-like illness. Epoetin theta was authorized for medical use in the European Union in October 2009. It is on the World Health Organization's List of Essential Medicines.
attribution contains material copied from Biopoin | European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin 2021